A Novel Multiplex Cell Viability Assay for High-Throughput RNAi Screening
暂无分享,去创建一个
Erich E. Wanker | Michael Boutros | Kubilay Demir | M. Boutros | E. Wanker | Anja Fritzsche | Kubilay Demir | Katja Muehlenberg | G. Erdmann | Gerrit Erdmann | Daniel F. Gilbert | Xian Zhang | Anja Fritzsche | Andreas Jaedicke | Katja Muehlenberg | Xian Zhang | A. Jaedicke | K. Demir
[1] H. Pijl,et al. Systemic energy homeostasis in Huntington's disease patients , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[2] D. Ehrnhoefer,et al. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.
[3] A. Tolkovsky,et al. Cytoplasmic Inclusions of Htt Exon1 Containing an Expanded Polyglutamine Tract Suppress Execution of Apoptosis in Sympathetic Neurons , 2008, The Journal of Neuroscience.
[4] D. Melton,et al. Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens. , 2003, Molecular cancer therapeutics.
[5] L. Neckers,et al. Hsp90 phosphorylation, Wee1 and the cell cycle , 2010, Cell cycle.
[6] J. Lucas,et al. Nuclear localization of N‐terminal mutant huntingtin is cell cycle dependent , 2002, The European journal of neuroscience.
[7] G. Hampton,et al. RNAi and HTS: exploring cancer by systematic loss-of-function , 2004, Oncogene.
[8] R. Larsson,et al. A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. , 1989, Anticancer research.
[9] J. Olson,et al. Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.
[10] Jeffrey C. Erlich,et al. Phospholipid‐Metabolizing Enzymes in Alzheimer's Disease: Increased Lysophospholipid Acyltransferase Activity and Decreased Phospholipase A2 Activity , 1998, Journal of neurochemistry.
[11] D. Silver,et al. Synthetic lethality--a new direction in cancer-drug development. , 2009, The New England journal of medicine.
[12] D. Rubinsztein,et al. Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation* , 2002, The Journal of Biological Chemistry.
[13] N. Déglon,et al. Implication of the JNK pathway in a rat model of Huntington's disease , 2009, Experimental Neurology.
[14] Edoardo Marcora,et al. The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus. , 2010, Human molecular genetics.
[15] L. Cope,et al. Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc , 2010, Oncogene.
[16] M. Giacomello,et al. Huntington's disease, calcium, and mitochondria. , 2011, BioFactors.
[17] M. MacDonald,et al. Identification of compounds which inhibit cytotoxicity associated with mutant Huntingtin protein expression , 2011 .
[18] S. Humbert,et al. Mutant huntingtin‐impaired degradation of β‐catenin causes neurotoxicity in Huntington's disease , 2010, The EMBO journal.
[19] R. Holcombe,et al. Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. , 2010, International journal of molecular medicine.
[20] Oliver Pelz,et al. web cellHTS2: A web-application for the analysis of high-throughput screening data , 2010, BMC Bioinformatics.
[21] M. Loureiro-Dias,et al. Flow Cytometric Assessment of Membrane Integrity of Ethanol-Stressed Oenococcus oeni Cells , 2002, Applied and Environmental Microbiology.
[22] Michael Boutros,et al. High‐throughput RNAi screening to dissect cellular pathways: A how‐to guide , 2010, Biotechnology journal.
[23] A. Giaccia,et al. Harnessing synthetic lethal interactions in anticancer drug discovery , 2011, Nature Reviews Drug Discovery.
[24] Nick S. Jones,et al. Connecting Variability in Global Transcription Rate to Mitochondrial Variability , 2010, PLoS biology.
[25] I. Vincent,et al. Constitutive Wee1 activity in adult brain neurons with M phase-type alterations in Alzheimer neurodegeneration. , 2001, Journal of Alzheimer's disease : JAD.
[26] M. Adolphe,et al. A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. , 1995, Journal of immunological methods.
[27] M. Chiang,et al. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. , 2011, Biochimica et biophysica acta.
[28] Matthew D. Ringel,et al. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors , 2010, Molecular and Cellular Endocrinology.
[29] B. Gatto,et al. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Earnest,et al. Circadian rhythms of extracellular ATP accumulation in suprachiasmatic nucleus cells and cultured astrocytes , 2009, The European journal of neuroscience.
[31] F. Ataullakhanov,et al. What Determines the Intracellular ATP Concentration , 2002, Bioscience reports.
[32] J. Olson,et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. , 2009, Cancer research.
[33] J. Caviston,et al. Huntingtin coordinates the dynein-mediated dynamic positioning of endosomes and lysosomes , 2011, Molecular biology of the cell.
[34] G. Johnson,et al. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease , 2010, Journal of bioenergetics and biomembranes.